A Model of Regulatory Burden in Technology Diffusion: The Case of Plant-Derived Vaccines. by Castle, David et al.
AgBioForum, 12(1): 108-118. ©2009 AgBioForum.
Introduction
One of the outcomes of the World Summit for Children
in 1990 was a call for the development of new vaccines
and vaccine technologies. It was proposed that the ideal
vaccine should be (1) administered as a single dose,
preferably oral, (2) effective when given near birth, (3)
heat stable, and (4) comprise multiple antigens. Last, but
not least, vaccines should be affordable. Many scientists
worldwide took up the challenge set out in the World
Summit declaration, including researchers interested in
the concept of developing plant-derived vaccines
(PDVs). Based on transgenic plant technology, the PDV
research concept has been proven, promising products
have been created, and all indications are that remaining
scientific and technological challenges are surmountable
(Das, Phillips, & Khachatourians, 2008). It is now time
to think about how PDVs would work if introduced into
the market. While it is not realistic to expect the com-
mercialization of this technology in the immediate
future given that many developments, and regulatory
and institutional hurdles remain to be overcome, its
prospects for commercialization are nevertheless inter-
esting to examine in a prospective model using a struc-
tured dynamic approach.
The model and the results presented in this article
are hypothetical and prospective. While analogous to
case study research, retrospectively focused, the study
presented in this article explores—from a prospective
standpoint—the problem of biotechnology diffusion for
health care applied to the hypothetical commercializa-
tion of a PDV against hepatitis B in India. India was
chosen as the setting to examine the technology diffu-
sion problem of PDVs for three main reasons. First, this
country must manage a high rate of contamination of the
hepatitis B virus, but it has only partially adopted immu-
nization programs. Second, India could become a prime
candidate for the introduction of this biotechnology, as it
has been making efforts to attract biotechnology R&D,
and it is also a country where new biotechnology prod-
ucts originate (Mani, 2004; Mehra, 2001). Third, India
possesses an institutional and legal framework that sup-
ports the utilization of biotechnology products, and it
has been a member of the WTO since 1995.
It therefore becomes inherently interesting to
observe the potential health impacts related to the diffu-
sion of PDVs on the population in developing countries.
One of the key working hypotheses that underlies this
work is that the system of technology diffusion is
assumed complex due to the time and interrelationship
dynamics amongst variables. This research case uses a
system-dynamics (SD) model to examine the market
introduction in India of a PDV against hepatitis B as a
substitute for the traditional vaccine technology. The lit-
erature on SD provides examples for looking at issues
associated with the adoption and diffusion of new prod-
ucts (Maier, 1998; Milling, 2002), the introduction of
medical technology (Homer, 1987), and health care pol-
icy (Hirsch, 2004; McDonnell, 2004).
The goal of this article is to examine the impacts and
repercussions through time of the potential commercial-
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ization of PDVs. As far as technology diffusion goes,
this article is concerned with three aspects of that prob-
lem: (1) the demographic evolution of India, (2) the
propagation of the virus in infant and non-infant
cohorts, and (3) the potential access by the population to
that biotechnology product. Given the exploratory
nature of this work, and the paucity of hard data to build
a “definitive” model, little attention is paid at this time
in this study to institutional issues associated with the
introduction of the technology. This is not because these
issues are not important—quite to the contrary. The cur-
rent scope of the model can be used as a starting point to
examine more narrowly the technology diffusion prob-
lem from an economic and managerial perspective prior
to enlarging it to broader legal and institutional consid-
erations, which would be essential to fully examine the
questions raised in this article. Obviously, a more trans-
disciplinary perspective would be required to look into
these issues (Gold et al., 2004) and to expand the scope
of the following model.
The remainder of the article is organized such that
the next section provides background information on
hepatitis B, and the following section describes the
research method. An influence diagram of the model is
then presented and briefly described. The accompanying
level-rate model is discussed. Some illustrative simula-
tion results are presented prior to presenting our conclu-
sion.
Hepatitis B Prevalence
Hepatitis B is a disease much more serious than many
realize. The virus is more infectious than HIV, and is the
second-most common carcinogen after tobacco. HepB is
also highly prevalent—an estimated 350 million people
worldwide are chronically infected, and HepB results in
approximately 900,000 deaths per year (Organization
for Economic Cooperation and Development [OECD],
2003). Hepatitis B is the foremost cause of cancer
deaths in males in sub-Saharan Africa and much of
Asia, as well as a significant cause of morbidity among
women in these regions (Kong et al., 2001). The out-
comes of HepB infection are age-dependent and include
acute or clinically visible hepatitis B, chronic HepB
infection, cirrhosis, and hepatocellular carcinoma. Chil-
dren infected with HepB seldom acquire acute HepB,
but up to 90% develop into chronic carriers and, hence,
become future sources of HepB infection causing acute
and chronic infection (Program for Appropriate Tech-
nology in Health [PATH], 2005). Infants and young chil-
dren have the highest risk of contracting HepB. Despite
this, however, the vaccine—which is 95% effective in
preventing the development of chronic infection in
childhood—covers just 50% of the world’s annual birth
cohort (PATH, 2005).
Research Methods
The model design follows the steps outlined in Sterman
(2000). First, the problem was defined, as well as the
objective of the model. The fundamental idea underly-
ing the model design is to observe the diffusion of the
PDV into the market and its effects on the population
given market assimilation of the technology. Second, we
used an influence diagram (ID) to formulate the
dynamic hypothesis that represents the structure of the
dynamics of hepatitis B propagation and the PDV adop-
tion with respect to the substitution with existing tech-
nology in relation to the evolution of the population in
India. Third, we converted the dynamic hypothesis into
an SD level-rate model. That model was calibrated with
data collected from publicly available information from
many sources. As will be discussed however, the avail-
ability of data remains an issue. The design of the model
is also an opportunity to identify data needs. Fourth, we
evaluated the model for consistency. Due to the very
nature of the prospective case under study, this model-
ing step was difficult to execute with respect to histori-
cal consistency. This dimension of the model evaluation
was conducted for the historical part of the model only
for which data was available. Fifth, the model generated
illustrative results.
The consultation of several data sources has proven
most useful in providing the information and expertise
necessary to build the model and, in particular, to iden-
tify underlying feedback loops. The data supporting this
model has been updated from the data presented at the
PICMET (Portland International Center for Manage-
ment of Engineering and Technology) conference in
Cape Town, South Africa in July 2008. Specifically,
ProVacs (a research group at the Biodesign Institute at
Arizona State University) updated the data used for cost
estimates and PDV production. The latest research
released from the ProVacs group indicates that the cost
for PDVs would be $0.02 less than what was used in the
previous model. In addition, all of the values for the
input parameters for PDV production were updated
using data released by the ProVacs group in 2006.
Diffusion of PDV: Dynamic Hypothesis
The structure of the dynamic hypothesis showing the
main feedback loops of the model is shown in Figure 1,AgBioForum, 12(1), 2009 | 110
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with key time delays highlighted (see the double bars).
The dynamic hypothesis contains 21 balancing feedback
loops and three reinforcing feedback loops. There are
three main sets of interrelationships represented within
this structure. The population dynamic distinguishes
between the infant (0 to 4 years old) and the non-infant
cohort (5 years old and over). An important dynamic is
the virus propagation in both infant and non-infant pop-
ulations. The inherent dynamics of PDV diffusion are
modeled.
General Population Dynamics
The term “infant population” refers to the population
between the age of 0 and 4, and the non-infant popula-
tion defines the population above age 5. The reinforcing
feedback loop R1, represents the interaction between
these two population cohorts by the influence of the
variable “birth rate.” The balancing loops B1 and B2 are
related to infant and non-infant mortality rates that
affect their respective cohort population.
Virus Propagation Dynamics
The virus propagation dynamics in the overall popula-
tion are shown in the set of balancing feedback loops
labeled B3 to B8. These relationships include the level
of infection in the overall population, referred to as
“infected population,” and the disaggregation of the
population between acute and chronic cases. Although
not shown in Figure 1, these feedback loops also sepa-
rate this dynamic for both infant and non-infant cohorts.
Figure 1. Influence diagram of PDV diffusion.AgBioForum, 12(1), 2009 | 111
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PDV Diffusion Dynamics
The modeling of PDV diffusion takes into account rela-
tionships relative to production, sales, and production
costs. The balancing loops B9 to B17 represent steps
that must be executed prior to PDV commercializa-
tion—that is, steps from plant production to vaccine
storage. More precisely, “production” refers to the num-
ber of hectares under production. However, it is likely
that production output will not be on par with the set
objective as soon as infrastructures are put into place—
that is, when greenhouses are put under production. The
number of hectares in production will increase over a
number of years to reach the desired production objec-
tive, and this is represented in balancing loop B9. Fol-
lowing this, a certain biomass is extracted from this
production. This biomass extraction is conducted in
three steps: mechanical process, concentration wash,
and the formulation that leads to vaccine production.
There is wastage generated at each step, and this process
slows down the PDV product output. The dynamics
inherent to this transformation process are described by
the balancing loops B10 to B16. The PDV ready for dif-
fusion, or the PDV stock, depends on the number of
PDVs produced (taking into account the import time
delay of PDVs) in case the producing country differs
from the diffusion one. This is captured by the balancing
loop B17.
Regarding sales, the dynamics represented in Figure
1 are analogous to production diffusion and technology
substitution. PDVs can be seen as a substitute to con-
ventional vaccines. The sales of innovative vaccines
refer to the sales of conventional vaccines, and the sale
of imitative vaccines refers to PDV sales. Likewise, the
population targeted by the vaccination program is
shown as market potential, and individuals that have
used one or the other vaccine are referred to as adopters.
These mechanisms of double diffusion, illustrated by
the balancing loops B18 to B20, are thus linked, on the
one hand to the existing market for conventional vac-
cines, and on the other hand, to the emerging market of
PDVs, according to production levels.
The remaining aspect to consider relative to the dif-
fusion of PDVs is vaccination costs. The PDV cost per
dose represents the effective cost for one dose, including
production and administration costs. The assumption is
that unit cost diminishes during a time interval to even-
tually stabilize. The time delay required is about the
same as the time it takes to adjust production (B9), and
this phenomenon is represented by the balancing feed-
back loop, B21. The total PDV cost is thus a function of
the PDV cost per dose and of the number of doses
required, but also includes additional costs linked to the
regulatory burden. Finally, the total cost of vaccination
accumulates costs associated with the total number of
vaccines sold. The impact of this third subsector (PDV
diffusion) on the propagation of the hepatitis B virus is
important as the number of vaccinated persons (or num-
ber of adopters) reduces the infected population (as seen
in reinforcing feedback loops R2 and R3).
Diffusion of PDV: The Simulation Model
Model Structure
The influence diagram shown in Figure 1 defines the
blueprint for the simulation model. Given the nature of
the problem examined, the model computes results on
an annual basis. Note that all the feedback loops shown
in the influence diagram are part of a large level-rate
model. This overall model can be split into five main
subsectors. We “sliced” the model into five subsectors.
• Demographic evolution in India
• Virus propagation—infant population and non-
infant population
• Market potential for PDV and vaccine diffu-
sion—infant population and non-infant popula-
tion
• PDV production, including time delays due to the
regulatory burden
• Estimation of vaccination program costs, includ-
ing costs due to the regulatory burden
Hence, the propagation of the virus in India, for both
infant and non-infant cohorts, was modeled and quanti-
fied according to the demographic evolution over time
of the infant and non-infant cohorts. More specifically,
hepatitis B (chronic versus acute infections), related
deaths, and infection recoveries were all included in the
model. The hepatitis B infection rates are estimated
through the birth cohorts. The vaccination rate is thus
dependent on the diffusion of the PDV in India, mea-
sured by the potential market and adopters. The quantity
of PDV available in the market for a given period is
directly linked to the production and distribution pro-
cess of vaccines. This process is therefore directly sub-
ject to certain time delays and costs, according to the
different regulations to consider during the diffusion of
a new biotechnology product.AgBioForum, 12(1), 2009 | 112
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Model Calibration
The parameters of the base-case level-rate model were
set using data collected from publicly available sources.
However, much of the data and information are not
directly available. Due to the hypothetical nature of the
problem modeled, only part of the results could be eval-
uated for historical accuracy. Table 1 shows the input
parameters used in the model and their sources. Some
entries are based on estimates of what they may be,
given extraneous information. The reference year for the
model evaluation is 1995. Relative to the demographic
evolution of India, the simulated results were quite com-
parable to the available historical data. This evaluation
was conducted using past and future population esti-
mates available for the period 1995-2015 (United
Nations, 2006).
Relative to the fraction of the population infected
with the hepatitis B virus, no specific time series was
available. The model was calibrated using data from a
study conducted by the World Health Organization
(WHO South-East Asia Regional Office [SEARO],
2002) that has estimated the number of infected cases,
the number of virus carriers, number of deaths from the
disease, etc. This data was also useful for looking into
the rates of new infant cohorts.
Data on PDV Production and Distribution
The model assumes that a PDV would be available on
the market starting in 2010. The real year for diffusion
initiation could, in fact, take place later due to certain
regulatory time delays imposed by different types of
regulation. Three assumptions were made for the esti-
mation of data relative to PDV production. First, follow-
ing the same assumption of ProVacs (2006), it was
supposed that 75 million doses of PDV should be pro-
duced annually and, thus, 25 million vaccines. The tar-
Table 1. Model parameters: Base case specification (t0=1995).
Input parameters Value Source
Data on population in India
Initial population (0- 4 years old) 119,212,928 United Nations (2006)
Initial population (5 years and greater) 812,138,072 United Nations (2006)
Birth coefficient from 0.03 to 0.02 Estimated from United Nations (2006)
Infant death coefficient from 0.02 to 0.01 Estimated from United Nations (2006)
Non-infant death coefficient 0.008 Estimated from United Nations (2006)
Delay cohort in years 5
Data on hepatitis B infection in India
Initial infection infants 14,000,000 Estimated from WHO SEARO (2002)
Infant infection rate 0.1 Estimated from WHO SEARO (2002)
Chronic infection rate for infant 0.35 WHO SEARO (2002), WHO Department of Communicable 
Diseases Surveillance and Response (CSR) (2002)
Acute infection rate for infant 0.01 WHO CSR (2002)
Death rate from chronic infant infection 0.2 Estimated from WHO SEARO (2002)
Initial infected population  162,000,000 Estimated from WHO SEARO (2002)
Infection rate of at risk individuals 0.2 Estimated from WHO SEARO (2002)
Rate of chronic cases 0.05 WHO SEARO (2002), WHO CSR (2002)
Rate of acute deadly infection  0.001 Estimated from WHO SEARO (2002)
Death rate from chronic infection  0.15 WHO SEARO (2002), WHO CSR (2002)
Data on traditional vaccines
Infant vaccination rate 0.01 Estimated for Southeast Asia (UNICEF, 2003)
Non-infant vaccination rate 0 Assumption
Efficacy of vaccines (%) 0.95 UNICEF (2003), WHO SEARO (2002), WHO CSR (2002)
Cost of conventional vaccines (US$) 1.26 ProVacs (2006; 3 doses at US$0.42)AgBioForum, 12(1), 2009 | 113
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geted production level will be met after a certain time,
thus initial production would be lower. Second, PDVs
would be produced in greenhouses and not in open
fields, because according to ProVacs (2006), the green-
house scenario is the most appropriate. Third, the plant
used for the biotech vaccine would be tobacco—which
has the highest cost per acre of production (ProVacs,
2006)—and not potato, tomato, or wheat.
The effective cost of one PDV dose was determined,
and it includes both production and administration costs.
The initial proposed cost for a PDV dose should experi-
ence a reduction prior to stabilizing after some time.
These cost estimates were provided by the research
work conducted by ProVacs (2006). The initial cost cor-
responds to the effective cost estimated for a single
dose, while the reduced cost is an estimated cost for a lot
of ten doses.
The last dimension to be quantified includes costs,
time delays, and the degree of certainty, linked to the
regulatory burden. These data had to be estimated for







The time delays associated with the first five types
of regulation slow down the beginning of PDV produc-
tion; these delays impact only the initial year of produc-
tion. Time delays linked to PDV imports intervene only
when the producing country differs from the final desti-
nation. It no longer slows down the beginning of pro-
duction, but the number of doses on the market. The
greater the certainty about each regulation type, the
greater the time delay.
A temporal PDV product development plan is illus-
trated in Figure 2. In this ideal plan, all development
stages (process, manufacturing/facility, intellectual
property rights, clinical, and regulatory) happen simul-
taneously, minimizing the time delay between clinical
development completion and public access to PDVs.
Costs associated with the first three types of regula-
tory burden intervene only in the initial year of PDV
production. Inversely, the last three types of regulation
generate costs to account for each PDV put on the mar-
ket. In this case, regulatory certainty is also taken into
account, increasing the risk for higher costs.
It is important to recall that the effective cost of a
PDV and the regulatory burden (costs, time delays, and
certainty) depend upon the country where the PDV is
produced and where distribution is controlled. Data
were collected for each of the following three scenarios
(further explained in Table 2).
Figure 2. Temporal PDV product development plan.AgBioForum, 12(1), 2009 | 114
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1. Production and distribution of the PDV is con-
trolled by developed nation (United States).
2. Production of the PDV is controlled by devel-
oped nation (United States), and distribution is
controlled by India.
3. Production and distribution of the PDV is con-
trolled by India.
Simulation Results
The designed and calibrated simulation model tested
and compared alternative scenarios. The commercializa-
tion year for the PDV was set to 2010, and the time
delay required for adjustments in production and in
costs was established at three years for each scenario.
Moreover, for the purpose of the calculations presented,
the assumption is that the PVD is not available in quan-
tities large enough to satisfy the need, and there is still a
penetration rate of 1% for the existing vaccine.
The repercussions generated by the alternative sce-
narios have been compared with a business-as-usual
baseline. “Business as usual” refers to a situation with-
out PDV introduction; only the conventional vaccine is
available. In accordance with the data presented in Table
1, only 1% of children are vaccinated.
The three hypotheses identified earlier have led to
the estimation of three scenarios. The results presented
in this section have an objective of comparing the
hypotheses for the
• swiftness of the PDV production process (Figure
3),
• number of new infected cases by the hepatitis B
virus per year (Figures 4 and 5),
• mortality associated with these new infected
cases (Figures 6 and 7), and
• total cost of vaccination (Figures 8 and 9).
The number of hectares in annual production provides
the swiftness of the production process. These results
are shown in Figure 3.
As mentioned earlier, the market opens for the PDV
in 2010. However, according to the scenarios, the time
delays associated with the regulatory burden interfere.
The results shown in Figure 3 indicate that for Hypothe-
ses 1 and 2, the PDV production would begin in 2016,
after a time delay of 6 years; for Hypothesis 3, it would
begin in 2027, after a time delay of 17 years. It appears
that for regulatory reasons, the time delay would be
much longer if India produced the PDV, not the United
States. Moreover, it is important to note that the results
Table 2. Summary of the three possible scenarios for PDV diffusion.
Summary
Scenario 1 PDVs are produced in the United States and distributed in India by a US firm. Production must meet US regulatory 
standards regarding containment and confinement practices. Finished product must meet US drug and biologic 
regulations. These regulations ensure product safety and efficacy but are expensive. India is open to foreign 
investment, but firms must undertake due diligence to ensure intellectual property rights protection. Import tariffs 
must be reviewed, and the distribution firm may be subject to review by the Reserve Bank of India.
Scenario 2  PDVs are produced in the United States by a US firm but distributed in India by an Indian firm. US environmental 
regulations and regulations for the finished product safety and quality apply. The US firm would likely negotiate a 
license with the Indian firm to distribute the final product, including licenses for intellectual property rights. In this 
scenario, the burden of foreign investment barriers is traded for licenses and importation tariffs. Like Scenario 1, the 
burden of US regulation in the United States, and the high cost of production must be considered.
Scenario 3 Scenario 3 involves the production and distribution of the PDV in India by an Indian firm, requiring compliance with 
Indian environmental and manufacturing standards, which may not be as stringent as in the United States. Several 
Indian authorities have regulatory jurisdiction over the commercialization of biotechnology, making the regulatory 
pathway somewhat uncertain and slow. Biosafety is a concern and appears in many regulations, including the 
Indian Patent Act. While the technology would be licensed, importation and tariff rules no longer apply.
Figure 3. PDV production.AgBioForum, 12(1), 2009 | 115
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generated are coherent with the assumption of time
delays required to reach targeted production levels of
3.25 hectares. For each of the hypotheses, the adjust-
ment is realized over a 3-year period. The target is
reached in 2019 for Hypotheses 1 and 2 and in 2030 for
Hypothesis 3.
Figures 4 and 5 present the repercussions of each
hypothesis and of “business as usual” on the new infec-
tion cases by the hepatitis B virus in India per year. Fig-
ure 4 presents infant new infection levels for each birth
cohort. Figure 5 displays new infection levels for non-
infant cohorts, but for which infection will occur later in
life.
The results presented show that the diffusion of
PDVs, no matter what the scenario, contributes to a
reduction in new infected cases per year. Indeed, by
2050, a reduction of nearly 84% in the total number of
new infections could be achieved. The number of new
infections declines soon after the introduction of PDVs.
It can be observed, however, that this figure never
reaches zero. Two reasons explain this outcome. First,
all vaccines, whether conventional or PDV, are not
100% reliable. More precisely, 95% of the individuals
vaccinated could nevertheless develop an infection. Sec-
ond, the targeted PDV production, set at 25 million vac-
cines, is not sufficient to cover all newborns, given the
increase in the number of newborns.
Finally, the comparison of results for the three sce-
narios stresses that the reduction in the number of
infected cases is slightly more effective in Scenario 2
than in Scenario 1. This is due to the more prevalent
time delays and regulatory certainty of imports in Sce-
nario 1. Regarding Scenario 3, the reduction witnessed
is much slower than for the other two scenarios. These
results are consistent with the analysis conducted earlier
regarding the swiftness of the PDV’s production pro-
cess. The production of PDVs, if first conducted in
India, could only begin 17 years after 2010, compared to
6 years for Scenarios 1 and 2, where production first
takes place in the United States.
Figures 6 and 7 present the repercussions of each
scenario—and of the status quo (without PDV commer-
cialization)—on the number of deaths due to the hepati-
tis B virus per year in India. Figure 6 shows the impact
of the uptake of the new technology on infant deaths,
while Figure 7 presents the number of non-infant deaths
that could be avoided.
As emphasized earlier, in connection with the reduc-
tion in the number of infected cases, the number of
deaths due to hepatitis B could decline rapidly if PDVs
are commercialized. Indeed, beginning in 2023—com-
pared with the status quo—a reduction of 35,102 deaths
is expected in Scenario 1 and 162,008 deaths in Sce-
nario 2 (in both infant and non-infant cohorts). In Sce-
nario 3, deaths will not be reduced until 2034, when (for
that year only) 105,686 deaths will be avoided. From
2010 to 2050, it appears that a total of 5.9 million deaths
would be avoided in Scenario 1, 6.3 million deaths in
Scenario 2, and 3.8 million deaths in Scenario 3. As
identified earlier, the differences in these numbers are
due to the speed at which the PDV production process
can be initiated. Based on these results, Scenario 3
slows the process of PDV diffusion the most. It is there-
fore clear that the impact of time of PDV diffusion on
mortality rates is non-negligible. Although Scenarios 1
and 2 are only slightly different, the health benefits
remain important in the case of the second hypothesis.
Figure 4. Infant infection: Newly infected per year. Figure 5. Non-infant infection: Newly infected per year.AgBioForum, 12(1), 2009 | 116
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Finally, the results were examined for their effects
on costs. Figures 8 and 9 present these results.
Prior to the production and distribution of PDVs, the
costs only relate to the sales of the conventional vaccine,
and it approximates about 1.5 million dollars (the
assumption is that only 1% of infants are vaccinated in
each year). From the time the PDVs are commercial-
ized, there is an increase in cost that varies according to
the scenario under consideration. In 2050, the annual
cost reaches $13.3 million, $12.81 million, and $5.48
million, respectively for Scenarios 1, 2, and 3. Scenarios
1 and 2 show a slight difference between their respective
annual costs. Similarly, with respect to the results in
Figure 8, it appears that the total cost of the vaccina-
tion—that is, the cumulative costs from 2010 to 2050—
differs according to scenarios. Total costs are $348.36
million in Scenario 1, $362.93 million in Scenario 2,
and $133.25 million in Scenario 3. According to these
findings, Scenario 2 generates the highest costs and Sce-
nario 3 generates the lowest costs.
These comparative analyses have highlighted that
Scenario 2 generates the largest benefits with respect to
reduction in the number of infected cases and mortality
related to the hepatitis B virus. This can be explained by
the fact that the time delays are less important for this
scenario than for the other two. In addition, the costs
generated by this scenario, while higher, are fairly close
to those of Scenario 1. In Scenario 3, costs are signifi-
cantly lower, but health benefits would take much lon-
ger to obtain. These results indicated that PDV
technology should be produced in the United States and
control over distribution should be executed in India.
Figure 8. Vaccination costs per year.
Figure 9. Total vaccination costs (from 2010 to 2050).
Figure 6. Deaths caused by hepatitis B: Infant population.
Figure 7. Deaths caused by hepatitis B: Non-infant popula-
tion.AgBioForum, 12(1), 2009 | 117
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Conclusion
The possible diffusion of PDV biotechnology in India
offers an alternative to existing, more expensive, con-
ventional vaccine technology that is currently available
on the market. The fact is that, in light of growing health
inequities aggravated by worsening wealth distribution,
the need for vaccines in poor and developing countries
has never been more pressing (Peny, Gleizes, &
Covilard, 2005). The development of new, safe, and
affordable vaccines and new vaccine delivery technol-
ogy for infectious diseases in developing countries is
crucial for the survival of hundreds of millions of peo-
ple, especially children (Global Alliance for Vaccine
Initiatives [GAVI], 2007). This article is concerned with
the potential impact that the introduction of such a tech-
nology could have on the incidence of hepatitis B cases
on India’s population overtime. The objective of the
article is to look at the hypothetical issues of PDV diffu-
sion using a system dynamics model. Some illustrative
results have been presented to show the interaction
between infection rates, mortality rates, vaccination
rates, and costs. The new ProVacs data used for the
model parameters provided updated predictions for the
number of deaths avoided due to vaccination, as well as
the cost to vaccinate. The updated data used in this
model from that presented at PICMET provides more
accurate and conclusive results for the overall benefit of
PDV technology, as well as further support for Scenario
2, the production of PDV in the United States and the
distribution by an Indian firm in India. In spite of prom-
ising features, such as much lower production costs,
institutional hurdles to a widespread diffusion of the
technology still need to be overcome.
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